INmune Bio Inc（INMB）股票分析

AI 分析 of INmune Bio Inc (INMB)

持有

Currently, INmune Bio Inc (INMB) is not a strong buy. The stock is trading at $1.38, which is significantly below its 52-week high of $2.60, indicating a decline of about 47%. Additionally, the RSI is at 29.024, suggesting that the stock is oversold. However, the forward P/E ratio is 0, indicating no expected earnings growth in the near term, which raises concerns about the company's profitability. The main risk is the significant net loss reported in Q2, which was $1.27 million, down from $24.46 million the previous year, but still indicates ongoing financial challenges. Therefore, while there are some positive catalysts such as the submission of an Orphan Drug Application, the overall financial performance and technical indicators suggest holding rather than buying at this time.

估值指标

INmune Bio Inc（INMB）当前预期市盈率为 0.00，5 年平均预期市盈率为 -3.83。

预期市盈率

严重高估

5 年均值 P/E

-3.83

当前P/E

0.00

高估

-2.62

低估

-5.04

预期 EV/EBITDA

合理

5 年均值 EV/EBITDA

-0.00

当前EV/EBITDA

0.00

高估

0.00

低估

-0.00

预期市销率

合理

5 年均值 P/S

1144.43

当前P/S

3.81

高估

3289.83

低估

-1000.97

Alphio AI 对 INMB 的价格情景

情景价格取自当年最后一个月度预测区间。概率为固定的模型权重（25 / 50 / 25），不构成保证。

乐

乐观

乐观 · 25%INMB

$23.16

情景价格

基

基准

基准 · 50%INMB

$15.12

情景价格

悲

悲观

悲观 · 25%INMB

$14.81

情景价格

INMB 常见问题 —— 由 Alphio AI 解答

INmune Bio Inc. is a clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. The Company has three product platforms. The Dominant-Negative Tumor Necrosis Factor (DN-TNF) product platform utilizes dominant-negative technology to selectively neutralize soluble TNF. DN-TNF product candidates are in clinical trials to determine if they can treat Mild Alzheimer’s disease, Mild Cognitive Impairment and treatment-resistant depression (XPro). The Natural Killer Cell Priming Platform includes INKmune, developed to prime a patient’s NK cells to eliminate minimal residual disease in patients with cancer and is in trials in metastatic castration-resistance prostate cancer. The third program, CORDStrom, is a proprietary pooled, allogeneic, human umbilical cord-derived mesenchymal Stromal/Stem cell (hucMSCs) platform that has completed a trial in recessive dystrophic epidermolysis bullosa. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Currently, INmune Bio Inc (INMB) is not a strong buy. The stock is trading at $1.38, which is significantly below its 52-week high of $2.60, indicating a decline of about 47%. Additionally, the RSI is at 29.024, suggesting that the stock is oversold. However, the forward P/E ratio is 0, indicating no expected earnings growth in the near term, which raises concerns about the company's profitability. The main risk is the significant net loss reported in Q2, which was $1.27 million, down from $24.46 million the previous year, but still indicates ongoing financial challenges. Therefore, while there are some positive catalysts such as the submission of an Orphan Drug Application, the overall financial performance and technical indicators suggest holding rather than buying at this time.